Once-Daily Adcirca® (tadalafil) Tablets for the Treatment of PAH

Power to move

Adcirca — the only once-daily phosphodiesterase type 5 (PDE-5) inhibitor for pulmonary arterial hypertension (WHO Group 1) that improves patients' exercise capacity.

Simple to start

Adcirca is taken by most patients as 2 tablets only once a day at the same time and is available at both retail and specialty pharmacies nationwide. Learn more about Adcirca.

Adcirca is simple with its:

  • Once-daily dosing
  • No requirement for monthly liver tests
  • Lack of titration for some patients
  • Ability to be taken with or without food
  • Availability at both retail and specialty pharmacies

Click here to read the results from the clinical trial.

Selected Important Safety Information for Adcirca:

Adcirca should not be used in patients taking medications that contain nitrates or other PDE-5 inhibitors. The most common side effects reported with Adcirca were headache (42%), muscle pain (14%), nasal swelling (13%), flushing (13%), respiratory tract infection (11%), extremity pain (11%), nausea (11%), back pain (11%), upset stomach (10%), and nasal congestion (9%).

We will be adding more features periodically, so Register for Updates and we'll send you an email to let you know when we add fresh tools and content to the site.

Indication

Adcirca is a phosphodiesterase type 5 (PDE-5) inhibitor for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.

Important Safety Information for Adcirca

CONTRAINDICATIONS

  • Adcirca should not be used in patients taking medicines that contain nitrates, as the combination could cause a sudden, unsafe drop in blood pressure.
  • Patients with a known serious hypersensitivity to tadalafil should not take Adcirca.

WARNINGS AND PRECAUTIONS

  • If a patient experiences anginal chest pain after taking Adcirca they should seek immediate medical attention.
  • Phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing Adcirca, physicians should carefully consider whether their patients with underlying cardiovascular disease could be adversely affected by such actions. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of Adcirca to these patients is not recommended.
  • The use of Adcirca with alpha blockers, blood pressure medications, and alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (fainting).
  • Tadalafil is metabolized predominantly by CYP3A in the liver. Use of Adcirca with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on Adcirca therapy that require treatment with ritonavir, Adcirca should be discontinued at least 24 hours prior to starting ritonavir. For patients on ritonavir therapy that require treatment with Adcirca, start Adcirca at 20 mg once a day. Use of Adcirca with potent inducers of CYP3A, such as rifampin, should be avoided.
  • The use of Adcirca is not recommended for patients with severe renal or hepatic impairment. Please see full prescribing information for dosing recommendations for patients with mild to moderate renal or hepatic impairment
  • Adcirca contains the same ingredient (tadalafil) as Cialis, which is used to treat erectile dysfunction (ED). The safety and efficacy of combinations of Adcirca with Cialis or other PDE-5 inhibitors have not been studied. Therefore, the use of such combinations is not recommended.
  • In rare instances, men taking PDE-5 inhibitors (including tadalafil) for ED reported a sudden decrease or loss of vision or hearing, or an erection lasting more than four hours. A patient who experiences any of these symptoms should seek immediate medical attention.

ADVERSE REACTIONS

  • The most common adverse event with Adcirca is headache (42% Adcirca vs. 15% placebo). Other common adverse events (reported by ≥ 9% of patients on Adcirca and more frequent than placebo by 2%) include myalgia, nasopharyngitis, flushing, respiratory tract infection, extremity pain, nausea, back pain, dyspepsia, and nasal congestion.

For more information about Adcirca, please see the Full Prescribing Information and Patient Information or call 1-800-545-5979.

Close Window

Leaving Adcirca.com

You have just clicked on a link that will take you outside the Adcirca website. United Therapeutics Corporation does not monitor, does not imply any endorsement, and is not responsible for the content on outside websites.


Click "OK" to proceed to this third-party website or "CANCEL" to return to Adcirca.com.


Close WindowClose Window
Close Window

Leaving Adcirca.com and going to the United Therapeutics Corporation website

You have just clicked on a link that will take you to the United Therapeutics Corporation website (Unither.com), which has information about Adcirca, as well as other medications.


Click "OK" to proceed to the Unither.com website or "CANCEL" to return to Adcirca.com.


Close WindowClose Window
Close Window

Leaving Adcirca.com and Going to the Living PAH Website

You have just clicked on a link that will take you outside the Adcirca website to the Living PAH website.


Click "OK" to proceed to the Unither.com website or "CANCEL" to return to Adcirca.com.


Close WindowClose Window
Close Window

Thank You for Registering!

If you would like to learn more about United Therapeutics Corporation, visit www.unither.com.


Close Window

Duplicate e-mail

The database has detected that you've already registered with this e-mail address. You do not need to register for updates again. Thank you for your interest in Adcirca!


Close Window

Functional Classifications of PAH

This classification was created by the New York Heart Association (NYHA) to measure the degree of disease severity in patients with PAH. The World Health Organization (WHO) developed a similar functional class system that is also commonly used in assessing patients with PAH.


Close Window

Thank You for Sharing Your Story!

Your story will now be considered for posting on Adcirca.com. Please note that not all submitted stories will be posted. Thanks for your enthusiasm and support!


Close Window

Electronic Reprint System
Mobile™ ePrint

Hello,

Welcome to the electronic reprint system. Your Mobile™ ePrint is ready for download.

We recommend that you “Save” the file to your desktop for portability.

*** IMPORTANT NOTICE ***
This Mobile™ ePrint is ONLY supported on the PC platform. Mac users please click here for support.

To save your ePrint – Please follow these steps:

Step 1. To download the file, click on the Download File link provided below.

Step 2. To save the file to your desktop, click the “Save” button.

Step 3. Locate the file on your desktop and double click to open.

Download File - LWW_161918_CP.exe

How do I launch my Mobile™ ePrint for the first time?

Simply click on the “Download File” link that is embedded in this email. You will be prompted to either “Run” or “Save” the ePrint file. We recommend you save the ePrint file to a location on your computer where you can locate and activate it at a later time. To open the saved ePrint file simply double-click on the file icon you saved to your computer. You must be connected to the Internet the first time you open your ePrint. This one-time Internet connection allows your ePrint to validate itself.

Click here for more information.

Please email us at requestinfo@tsp.sheridan.com for any ePrint support questions.

Thank you for your order!


Close Window

Coming soon! Register for Updates and we'll send you an email to let you know when we add fresh content to the site.

Close Window

Coming soon! Register for Updates and we'll send you an email to let you know when we add fresh content to the site.